Effect of the Janus kinase inhibitor tofacitinib in the treatment of juvenile scleroderma: A single-center experience

被引：0
|
作者：
Colussi, Lara [1 ]
Dagri, Arianna [2 ]
Pastore, Serena [3 ]
Tommasini, Alberto [1 ,3 ]
Pin, Alessia [3 ]
Taddio, Andrea [1 ,3 ]
机构：
[1] Univ Trieste, Dept Med Surg & Hlth Sci, Trieste, Italy
[2] Univ Udine, Dept Med DAME, Div Pediat, Udine, Italy
[3] Inst Maternal & Child Hlth IRCCS Burlo Garofolo, Trieste, Italy
来源：
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES | 2024年 / 27卷 / 08期
关键词：
LOCALIZED SCLERODERMA;
D O I：
10.1111/1756-185X.15295
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] JUVENILE SCLERODERMA: TREATMENT EXPERIENCE OF A SINGLE ONE CENTER
    Osminina, M. K.
    Geppe, N. A.
    Kostina, J. O.
    Afonina, E. Y.
    Shpitonkova, O. V.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (02) : S116 - S116
  • [2] TOFACITINIB TREATMENT IN CHILDREN WITH RHEUMATIC DISEASES: SINGLE-CENTER EXPERIENCE
    Kostik, M.
    Raupov, R.
    Suspitsin, E.
    Isupova, E.
    Gabrusskaya, T.
    Dubko, M.
    Snegireva, L.
    Masalova, V.
    Ermachenkova, T.
    Sorokina, L.
    Likhacheva, T.
    Kaneva, M.
    Gaidar, E.
    Kalashnikova, O.
    Chasnyk, V.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 247 - 248
  • [3] The Janus-Kinase-Inhibitor Tofacitinib
    Krome, Susanne
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2013, 51 (01): : 7 - 7
  • [4] Single-Center Experience With Epigenetic Treatment for Juvenile Myelomonocytic Leukemia
    Marcu, Andra
    Colita, Andrei
    Radu, Letitia Elena
    Jercan, Cristina Georgiana
    Bica, Ana Maria
    Asan, Minodora
    Coriu, Daniel
    Tanase, Alina Daniela
    Diaconu, Carmen C.
    Mambet, Cristina
    Botezatu, Anca
    Pasca, Sergiu
    Teodorescu, Patric
    Anton, Gabriela
    Gurban, Petruta
    Colita, Anca
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [5] Efficacy of topical tofacitinib, a Janus kinase inhibitor, in the treatment of plaque psoriasis
    Bagherani, Nooshin
    Smoller, Bruce R.
    DERMATOLOGIC THERAPY, 2017, 30 (03)
  • [6] Topical Tofacitinib: A Janus Kinase Inhibitor for the Treatment of Vitiligo in an Adolescent Patient
    Berbert Ferreira, Sineida
    Berbert Ferreira, Rachel
    Neves Neto, Afonso Cesar
    Assef, Silvana Martins Caparroz
    Scheinberg, Morton
    CASE REPORTS IN DERMATOLOGY, 2021, 13 (01): : 190 - 194
  • [7] Tofacitinib: The First Janus Kinase (JAK) Inhibitor for the Treatment of Rheumatoid Arthritis
    Vyas, Deepti
    O'Dell, Kate M.
    Bandy, Jason L.
    Boyce, Eric G.
    ANNALS OF PHARMACOTHERAPY, 2013, 47 (11) : 1524 - 1531
  • [8] Treatment of halo naevus with the topical Janus kinase inhibitor tofacitinib 1.5%
    Hu, W. T.
    Lin, F. Q.
    Xu, A. E.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2018, 43 (08) : 935 - 937
  • [9] Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment
    Strober, B.
    Buonanno, M.
    Clark, J. D.
    Kawabata, T.
    Tan, H.
    Wolk, R.
    Valdez, H.
    Langley, R. G.
    Harness, J.
    Menter, A.
    Papp, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2013, 169 (05) : 992 - 999
  • [10] Scleroderma Renal Crisis: A Large Single-center Experience
    Shah, Rushab
    Ross, Laura
    Morrisroe, Kathleen
    Stevens, Wendy
    Nikpour, Mandana
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 1238 - 1239
12345